Hubei Biocause Pharmaceutical (000627) — Net Asset Quality Index
Hubei Biocause Pharmaceutical (000627) has a Net Asset Quality Index of 12.6% as of September 2024. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥285.15 Billion minus total liabilities of CN¥249.15 Billion yields net assets of CN¥36.00 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check Hubei Biocause Pharmaceutical (000627) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Hubei Biocause Pharmaceutical Net Asset Quality Index Over Time (2000–2023)
This chart shows how Hubei Biocause Pharmaceutical's Net Asset Quality Index has evolved across 24 annual periods from 2000 to 2023. As of September 2024, the index stands at 12.6%, representing net assets of CN¥36.00 Billion against total assets of CN¥285.15 Billion CNY. See working capital position of Hubei Biocause Pharmaceutical to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Hubei Biocause Pharmaceutical (2000–2023)
The table below presents the year-by-year Net Asset Quality Index for Hubei Biocause Pharmaceutical from 2000 to 2023, covering 24 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see 000627 company net worth.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2023 | 11.1% | CN¥33.63 Billion | CN¥301.94 Billion | CN¥268.30 Billion | ▼ -0.9 pp |
| 2022 | 12.0% | CN¥34.60 Billion | CN¥288.60 Billion | CN¥254.00 Billion | ▼ -2.2 pp |
| 2021 | 14.2% | CN¥37.47 Billion | CN¥263.90 Billion | CN¥226.43 Billion | ▼ -0.2 pp |
| 2020 | 14.4% | CN¥34.59 Billion | CN¥239.40 Billion | CN¥204.81 Billion | ▼ -2.3 pp |
| 2019 | 16.7% | CN¥34.35 Billion | CN¥205.27 Billion | CN¥170.92 Billion | ▲ +2.1 pp |
| 2018 | 14.6% | CN¥26.01 Billion | CN¥178.25 Billion | CN¥152.24 Billion | ▼ -4.4 pp |
| 2017 | 19.0% | CN¥26.70 Billion | CN¥140.42 Billion | CN¥113.71 Billion | ▲ +1.7 pp |
| 2016 | 17.3% | CN¥20.40 Billion | CN¥117.88 Billion | CN¥97.48 Billion | ▼ -56.7 pp |
| 2015 | 74.0% | CN¥1.78 Billion | CN¥2.41 Billion | CN¥625.50 Million | ▲ +3.4 pp |
| 2014 | 70.7% | CN¥1.49 Billion | CN¥2.11 Billion | CN¥618.76 Million | ▲ +4.1 pp |
| 2013 | 66.6% | CN¥1.44 Billion | CN¥2.16 Billion | CN¥720.71 Million | ▼ -7.9 pp |
| 2012 | 74.5% | CN¥1.54 Billion | CN¥2.06 Billion | CN¥527.37 Million | ▼ -0.6 pp |
| 2011 | 75.1% | CN¥1.41 Billion | CN¥1.88 Billion | CN¥469.47 Million | ▼ -6.0 pp |
| 2010 | 81.1% | CN¥1.60 Billion | CN¥1.98 Billion | CN¥374.25 Million | ▲ +8.0 pp |
| 2009 | 73.0% | CN¥1.57 Billion | CN¥2.16 Billion | CN¥581.29 Million | ▼ -3.4 pp |
| 2008 | 76.4% | CN¥1.51 Billion | CN¥1.98 Billion | CN¥466.75 Million | ▲ +11.0 pp |
| 2007 | 65.4% | CN¥866.03 Million | CN¥1.32 Billion | CN¥458.52 Million | ▲ +3.4 pp |
| 2006 | 62.0% | CN¥723.71 Million | CN¥1.17 Billion | CN¥443.66 Million | ▼ -5.2 pp |
| 2005 | 67.2% | CN¥731.23 Million | CN¥1.09 Billion | CN¥356.70 Million | ▲ +0.3 pp |
| 2004 | 66.9% | CN¥723.91 Million | CN¥1.08 Billion | CN¥357.41 Million | ▲ +1.1 pp |
| 2003 | 65.9% | CN¥718.75 Million | CN¥1.09 Billion | CN¥372.22 Million | ▼ -4.6 pp |
| 2002 | 70.4% | CN¥768.02 Million | CN¥1.09 Billion | CN¥322.39 Million | ▼ -6.7 pp |
| 2001 | 77.1% | CN¥762.99 Million | CN¥989.09 Million | CN¥226.09 Million | ▲ +10.1 pp |
| 2000 | 67.1% | CN¥594.52 Million | CN¥886.33 Million | CN¥291.81 Million | — |